Neuland Labs.

Neuland Labs reported a flat performance for Q3 FY25, with total income rising just 1.8% YoY to ₹401.9 crores. Core profitability was under pressure, as EBITDA excluding exceptional item^📎s fell to ₹90.3 crores from ₹122.7 crores a year ago, with the margin contracting to 22.5% due to business mix and higher operational costs. The 9-month revenue showed a marginal 1.7% degrowth to ₹1,161.5 crores. This performance aligns with management's reiterated guidance for a 'relatively flat' FY25, marking it as a year of transition before the next growth phase.

The most significant announcement was a ₹254 crore CAPEX into peptide manufacturing capabilities. This investment is not tied to a single product but is a strategic platform build-out, encompassing large-scale commercial, pilot, and R&D facilities. Management plans to leverage this for both its generic (GDS) and custom manufacturing (CMS) businesses, with plans to file two generic peptide DMFs, including the high-potential GLP-1 molecule Tirzepatide. However, the company has guided for a 3-5 year ramp-up period, indicating this is a long-term strategic play with no immediate revenue impact.

The Custom Manufacturing Solutions (CMS) segment generated revenues of ₹156 crores in Q3. A key clarification during the call was the nature of the 9M development revenue, which appeared to decline sharply. Management explained this was due to a large molecule successfully transitioning from the pre-registration phase to commercial status at the end of Q2. Consequently, its revenue is now booked under 'commercial', explaining the shift. This indicates pipeline maturation rather than a slowdown in R&D activity.

Management was clear in setting expectations for the near term, confirming FY25 will be a flat year. This is a downward revision from the 'moderate growth' guided at the start of the year, attributed to shifts in dispatch schedules. However, they expressed strong confidence that growth will resume in FY26. This optimism is underpinned by the existing order pipeline and the expected commercialization of at least one new molecule from the pre-commercial stage in the next fiscal year.

Despite the flat growth, Neuland's financial health remains robust. The company reported a negative net debt of ₹185.1 crores, indicating a strong cash position. Over the first nine months, it invested ₹147 crores in capital expenditure while generating a free cash flow of ₹70.8 crores. This demonstrates the company's ability to internally fund its significant growth projects, including the new peptide facility, without stressing its balance sheet.